BDH Industries Limited (524828) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of BDH Industries Limited ₹201, price ₹482, upside -58.2%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch BDH Industries Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹90.03 – ₹584.61 · fair‑value band ₹152.21 – ₹270.15 · the ₹482.20 price screens above the ₹201.49 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow BDH Industries in your weekly email
Every Wednesday you see whether BDH Industries is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BDH Industries Limited manufactures and sells therapeutic formulations covering a range of pharmaceuticals in India.
Show more
BDH Industries Limited manufactures and sells therapeutic formulations covering a range of pharmaceuticals in India. It offers analgesic/antipyretic, analgesic balm, antacids, acaricide, anthelmintics, antiprotozoal, aniti-glaucoma, antiseptics, anti-psychotics, anti-tuberculosis, anti-allergics, anti-tussive, antiasthamatics, antibacterial, antiseptic, anticancer, anticoagulants, anticonvulsants, antidiabetics, anti-emetics, antifungal, antigout, antimalaraial, antiparkinsonisms, antispasmodics, and antiulcer pharmaceutical products. The company also provides antivirals, sedatives/anxiolytics/antidepressants, calcium supplements, cardiovascular products, carminatives/aromatics, corticosteroids, diuretics, drugs acting on uterus, electrolyte replinishers, expextorants, iron supplements, laxatives, local anesthetics, general anesthetics, mydriatics, narcotic-analgesics, non-steroidal anti-inflammatory products, rubefacient and mild analgesics, and pharmaceutical aid products. In addition, it offers skin protectives, skin smootheners, and vitamins, as well as SOULFIL, an oral pill for the treatment of erectile dysfunction in men. The company exports its products to the United States, Canada, Latin America, the Caribbean Islands, Europe, Russia, Gulf Countries, Australia, African countries, Asia, and Far East countries. BDH Industries Limited was founded in 1935 and is based in Mumbai, India.
Stock analysis
BDH Industries Limited (524828) currently trades at ₹482.20, while our model-based Fair Value estimate is ₹201.49, 58.2% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹494.17 per share, and 2 of the 17 models we run sit above the ₹482.20 price.
Bear case: the Dividend Discount group reads lowest at ₹68.06, and 15 of the 17 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹152.21 (bear) to ₹270.15 (bull), the price of ₹482.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Health Care sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
BDH Industries Limited reported revenue of ₹960M in FY2026 versus ₹694M in FY2022, a compound +8.4%/yr. Reported net income was ₹108M in FY2026, compounding +10.6%/yr from FY2022.
Key figures
Market cap ₹430M (≈ $4.5M) · P/E ratio 7.8 · P/S ratio 0.88 · EPS (TTM) ₹9.80 · Dividend yield 3.2% · Net margin 11.3% · Return on equity 14.8% · Return on assets (EBIT) 13.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 38% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Health Care peers we cover trades at −40% fair-value upside, at −58%, 524828 screens richer than that median.
Fair Value models
Bear ₹152.21Fair Value ₹201.49Bull ₹270.15
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹3.72 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+14.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.2%
Dividend (yield on the price)3.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11.2% vs 12.7%, steady
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 14%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 51 stocks
Beats the industry median on 8/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside−47.9% · Bottom 25%
Profitability
Return on equity (TTM)14.8% · Top 25%
Return on assets6.9% · Top 25%
Net margin (TTM)10.8% · Top 25%
Operating margin (TTM)13.7% · Top 25%
Growth and dividend
Revenue growth18.5% · Above median
Dividend yield (TTM)3.2% · Above median
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
P/E (TTM)7.8× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)93· sector 55
PAST (return on equity)59· sector 10
HEALTH (low debt)100· sector 98
DIVIDEND (yield)65· sector 26
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is BDH Industries Limited (524828) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹201.49 versus a price of ₹482.20, about −58% upside (overvalued).
What is the fair value of 524828?
Our model-based fair value for BDH Industries Limited is ₹201.49 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹482.20.
What is the quality score of 524828?
BDH Industries Limited has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BDH Industries Limited (524828)?
Our model-based price target is the fair value of ₹201.49 (as of Sep 24, 2026) from 17 valuation models. Cautious scenario ₹152.21, optimistic scenario ₹270.15. It is a calculation from audited fundamentals, not an analyst target.
What is the BDH Industries Limited stock forecast for 2026?
Our models put fair value at ₹201.49, about −58% upside versus a price of ₹482.20 (overvalued). Cautious scenario ₹152.21, optimistic scenario ₹270.15. The calculation is refreshed regularly with new filings.
What is the revenue of BDH Industries Limited (524828)?
BDH Industries Limited reported trailing-twelve-month revenue of about ₹522M (latest available figure, as of Sep 24, 2026).
Does BDH Industries Limited pay a dividend?
BDH Industries Limited currently shows a dividend yield of about 3.23% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of BDH Industries Limited (524828)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BDH Industries Limited it is ₹201.49 per share (as of Sep 24, 2026), against a price of ₹482.20. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is BDH Industries Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 524828 trades above its calculated fair value: price ₹482.20, fair value ₹201.49, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 524828?
No. The price is what the market pays today (₹482.20); the fair value is what the company's own numbers justify (₹201.49). For BDH Industries Limited the two are ₹280.71 per share apart. That gap is exactly why we show both numbers side by side.
How much is BDH Industries Limited worth?
The market values BDH Industries Limited at about ₹430M (market capitalisation, as of Sep 24, 2026). Per share that is ₹482.20; our models calculate a fair value of ₹201.49 per share.
What do the bullish and bearish scenarios say about 524828?
Our models span a range for BDH Industries Limited: cautious scenario ₹152.21, base ₹201.49, optimistic ₹270.15 per share (as of Sep 24, 2026, price ₹482.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 524828?
BDH Industries Limited trades at a price-to-earnings ratio of 7.8 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹201.49 is built from several models across several years.
How solid is the balance sheet of BDH Industries Limited (524828)?
Balance-sheet figures for BDH Industries Limited (as of Sep 24, 2026): return on equity 14.8%. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is 524828 from its 52-week high?
BDH Industries Limited trades at ₹482.20, about 18% below its 52-week high of ₹584.61 and 38% above the low of ₹348.36 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹201.49 is for.
Which stocks are comparable to BDH Industries Limited?
From the same area (Health Care) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BDH Industries Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹482.20, calculated fair value ₹201.49 (−58%), Quality Score 67/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 524828 calculated?
We run BDH Industries Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹201.49, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. BDH Industries Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BDH Industries Limited (524828)?
The closing price on Oct 1, 2026 was ₹482.20. Our model-based fair value is ₹201.49, about −58% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BDH Industries Limited right now?
The price sits above even our optimistic bull case (₹270.15). The favourable scenario is already priced in. Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of BDH Industries Limited
How large is the market capitalisation of BDH Industries Limited (524828)?
The market capitalisation of BDH Industries Limited is ₹430M (≈ $4.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BDH Industries Limited (524828)?
The price-to-sales ratio of BDH Industries Limited is 0.88 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BDH Industries Limited (524828)?
Earnings per share at BDH Industries Limited are ₹9.80 (price ÷ EPS = P/E 7.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of BDH Industries Limited (524828)?
The dividend yield of BDH Industries Limited is 3.2% (payout 159%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of BDH Industries Limited (524828)?
The net margin of BDH Industries Limited is 11.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BDH Industries Limited (524828)?
The return on equity (ROE) of BDH Industries Limited is 14.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BDH Industries Limited (524828)?
On an EBIT basis the return on assets of BDH Industries Limited is 13.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BDH Industries Limited (524828)?
The operating margin of BDH Industries Limited is 13.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BDH Industries Limited (524828)?
Revenue at BDH Industries Limited is growing +18.5% versus a year earlier (3y avg +8.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BDH Industries Limited (524828)?
Earnings per share at BDH Industries Limited are growing +45.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does BDH Industries Limited (524828) generate?
The free cash flow of BDH Industries Limited is −₹24.4M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch BDH Industries Limited in the live analysis
One click puts BDH Industries Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
